Option chain shows key data for Innovation Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Innovation Pharma.

Innovation Pharma (OTC:IPIX) Stock, Option Chain

Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.

News

Penny Stocks

Small Cap

Markets

ADDYY

AYRWF

BNPQY

ETHE

FMCC

FNMA

GBTC

IPIX

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

LTCN

NGLOY

RHHBY

SMURF

TRSSF

VRNOF

NLST

NVNSX

Photo by Markus Winkler on Unsplash

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

November was an interesting month for OTC Markets securities. 

These OTC Securities Had the Most Trading Activity in November

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

Trading Ideas

General

ACDVF

BYRN

CYDY

EXPGY

HGEN

PLNHF

SMICY

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Trading Activity In Emerging Names Increased On OTC Markets In June

Biotech

Long Ideas

Short Ideas

Emerging Markets

Specialty ETFs

Eurozone

Health Care

ETFs

ADRNY

AXAHY

DANOY

GAXY

HEINY

IMBBY

JBSAY

KBLB

TOMDF

MDNAF

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

The COVID-19 pandemic has led to dramatic changes in market behavior, as traders and investors try to grapple with the short-term and long-term implications of a pandemic.

The Spread of COVID-19 Has Caused Massive Volume Spikes In Securities On OTC Markets

INNOVATION PHARMACEUTICAL by Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Inc

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>)&nbsp;a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4340843-1&amp;h=149896997&amp;u=https%3A%2F%2Fldh.la.gov%2Fnews%2FH5N1-death&amp;a=Louisiana+Department+of+Health+recently+reported+the+first+U.S.+death+from+H5N1">Louisiana Department of Health recently reported the first U.S. death from H5N1</a>.

TCBP

TCBP Announces That It Intends To Begin Proof Of Concept Preclinical Studies For Its Lead Therapeutic TCB008, For Treatment In H5N1, Commonly Known As "Bird Flu"

Guidance

MYGN

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

JP Morgan analyst Tami Zakaria maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Neutral and raises the price target from $12 to $13.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on CNH Industrial, Raises Price Target to $13

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is gearing up to release its<a href="https://www.benzinga.com/quote/UNH/earnings"> fourth quarter earnings report</a>, and investors are watching closely. Stephanie Link, CIO at Hightower Advisors LLC, has dubbed the managed care giant the &#8220;number one company on sale&#8221; despite potential near-term earnings pressure.
<h2 class="wp-block-heading">&#8216;They&#8217;re Probably Gonna Miss&#8217; Q4 Earnings Expectations </h2>
With estimated earnings per share (EPS) of $6.73 and revenue projections around $101.75 billion according to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Benzinga Pro</a> data, UnitedHealth faces scrutiny over high utilization rates that could dent its profit margins. 
On earnings, &#8220;they're probably gonna miss&#8230;because utilization rates are so strong, so high, and it hurts their cost,&#8221; Link <a href="https://www.cnbc.com/video/2025/01/14/trade-tracker-stephanie-link-buys-unitedhealth.html">remarked</a> during CNBC's Halftime Report. 
However, she sees this as a temporary hiccup, not a long-term trend.
Read Also: <a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings">UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec&#8217;s Murder, Public Outcry Are Backdrop For Q4 Earnings</a>
<h2 class="wp-block-heading">From Beat-And-Raise To Strategic Patience</h2>
UnitedHealth, long celebrated for its consistent earnings beats, hasn't seen much stock movement in the past year, but that hasn&#8217;t dampened Link&#8217;s enthusiasm. &#8220;They have a gem with Optum,&#8221; she said, referring to the segment responsible for 24% of the company's revenue and 12% of operating profits. 
Ongoing M&amp;A activity is bolstering Optum's growth trajectory, even as the broader healthcare sector struggles to find favor with investors.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png" alt="" class="wp-image-734548" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM-300x233.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Technically, UnitedHealth shares are experiencing bullish buying pressure, with the stock trading above its eight, 20 and 200-day simple moving averages (SMAs).
At $543.74 per share, the price positions UNH stock as a bullish signal across these metrics, although its moving average convergence/divergence (MACD) indicator of a negative 6.15 suggests caution. Meanwhile, UNH stock&#8217;s relative strength index (RSI) of 56.86 signals moderate strength but room for additional upward movement.
<h2 class="wp-block-heading">A Buying Opportunity In The Making?</h2>
Historically trading at a premium valuation, UnitedHealth now sits at 17 times earnings, compared to its typical 21 times multiple. &#8220;When I owned it, it was trading at something like 25 times, and every quarter was a beat and raise,&#8221; Link noted. Despite the temporary pressure, she believes the stock&#8217;s visibility will only improve post-earnings.
Link remains bullish on UnitedHealth&#8217;s potential, citing strong fundamentals, a promising $18 billion buyback program and expectations of double-digit earnings and revenue growth ahead. &#8220;We&#8217;re gonna see double-digit growth in earnings and revenues,&#8221; she emphasized, viewing current regulatory and litigation concerns as mere &#8220;noise.&#8221;
UnitedHealth's premium status as the &#8220;number one managed care company&#8221; may make today&#8217;s market lull a golden opportunity for savvy investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/news/25/01/42776487/heres-how-much-you-would-have-made-owning-unitedhealth-group-stock-in-the-last-10-years">Here&#8217;s How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years</a></li>
</ul>
Photo: Shutterstock

Technicals

Previews

UnitedHealth: The 'Number One Company On Sale' Ahead Of Q4 Earnings Report

Benchmark analyst Christopher Kuhn reiterates RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) from Hold to Hold.

Reiteration

Benchmark Reiterates Hold on RXOto Hold

Expansion into South Africa &amp; Nigeria Marks Ispire's First International Nicotine License Arrangement &amp; Product Launch
LOS ANGELES, Jan. 15, 2025 /PRNewswire/ -- <a href="https://ispiretechnology.com/">Ispire Technology Inc.</a>&nbsp;("Ispire" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>), an innovator in vaping technology and precision dosing, announced the successful launch of its BrkFst nicotine products across South Africa and Nigeria, marking the Company's first international nicotine license arrangement and product launch. BrkFst, the brand co-created by GRAMMY-Award winner Burna Boy, is set to redefine the nicotine product market in these regions.

ISPR

Ispire Technology Announces License Arrangement And Successful Launch Of Burna Boy's BrkFst Nicotine Products Into African Markets

Offerings

AZTR

Azitra Prices 4,857,780 Share Public Offering Of Common Stock At $0.30/Share

NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced the rebranding of its recently acquired, patented Pylon Transportable Reactor Platform, which will now be known as LOKI MMR&#x2122;.
The LOKI MMR&#x2122; is a portable nuclear reactor designed for versatility in application and deployment. Designed to provide between 1.5MWe and 5MWe of power, it is tailored to specific applications ranging from remote terrestrial, marine, and space deployments. Its transportability via road, rail, sea, and air ensures adaptability for diverse deployment scenarios and supports scalability through interconnected systems to meet greater energy demands. While NANO Nuclear will explore different applications for LOKI MMR&#x2122;, it is anticipated that the LOKI MMR&#x2122; will particularly compliment NANO Nuclear's previously announced efforts to apply nuclear energy in space exploration.

NANO Nuclear Energy Announces LOKI MMR As The New Tradename For Its Newly Acquired Patented Pylon Transportable Reactor Platform

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has announced its inaugural Quantum Day, set to take place on Mar. 20 during the GTC 2025 event. The announcement comes just days after CEO Jensen Huang stated that practical quantum computing may <a href="https://www.benzinga.com/markets/equities/25/01/42867168/nvidias-jensen-huang-said-something-that-has-all-quantum-computing-stocks-tumbling-qubt-and-rgti-down-13-ionq-down-11">still be two decades away.</a>
What Happened: The event is set to spotlight the swift advancements in quantum computing, a technology expected to transform sectors like drug discovery, materials science, and financial forecasting. Huang will spearhead discussions with leaders from key industry players, including&nbsp;Alice &amp; Bob,&nbsp;Atom Computing, IONQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) and&nbsp;D-Wave (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), the company said in a&nbsp;blog post on Wednesday.
Quantum Day will offer sessions exploring both the current and future potentials of quantum technology. These sessions will be led by Huang and other experts from the quantum field. Additionally, a developer day session will emphasize collaborations between NVIDIA and its partners to advance quantum computing technologies.
Why It Matters: Last week, during Nvidia's Analyst Day, CEO Huang shared his optimism about the future of quantum computing but cautioned that practical applications could still be 15 to 30 years away. 
"If you kind of said 15 years for very useful quantum computers, that would probably be on the early side. If you said 30, it's probably on the late side," he said.
Huang&#8217;s comments were backed by Meta Platforms Inc. CEO Mark Zuckerberg. <a href="https://www.benzinga.com/markets/equities/25/01/42936751/mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-view-on-quantum-computing-its-still-quite-a-ways-off">During his appearance</a> on Joe Rogan's podcast Saturday, Zuckerberg admitted his limited expertise on the subject but aligned with the industry consensus, suggesting a decade-long timeline for the widespread adoption of quantum computing.
Meanwhile, despite Huang&nbsp;stating that practical quantum computing might be two decades away, NVIDIA is investing heavily in its future. The company is <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">strategically hiring to strengthen</a> its quantum computing capabilities. This indicates NVIDIA&#8217;s long-term commitment to integrating quantum and classical computing systems.
Moreover, the announcement comes at a time when quantum computing stocks are gaining momentum during Wednesday premarket. Following&nbsp;Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) declaration of making its business clients <a href="https://www.benzinga.com/markets/equities/25/01/42998134/qubt-qbts-up-12-rgti-gains-3-in-wednesday-premarket-quantum-computing-stocks-gain-momentum-after-microsoft-says-we-are-right-on-the-cusp-of-seeing-quantum-computers-solve-meaningful-problems">&#8220;quantum-ready&#8221; by 2025</a>, stocks like&nbsp;Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) and&nbsp;D-Wave Quantum&nbsp;have seen significant gains. This surge underscores the growing anticipation and investment in quantum computing technologies.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42993297/bitcoin-ethereum-and-dogecoin-rebound-sharply-on-lighter-inflation-data-top-trader-says-despite-expectations-for-bull-market-to-be-over-its-an-ideal-climate-for-altcoins">Bitcoin, Ethereum, And Dogecoin Rebound Sharply On Lighter Inflation Data: Top Trader Says Despite Expectations For Bull Market To Be Over, It&#8217;s An Ideal Climate For Altcoins.</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

IONQ

MSFT

NVDA

QBTS

QUBT

NVIDIA Announces First-Ever Quantum Day At GTC 2025, Days After Jensen Huang Said Quantum Computing Is 20 Years Away

Genius Sports Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) ("Genius Sports," the "Company," "we" or "our") announced today that it is reaffirming its previously disclosed 2024 guidance of Group Revenue of approximately $511 million and Group Adjusted EBITDA of approximately $86 million. Additionally, the Company reported its preliminary unaudited estimate of cash, cash equivalents and restricted cash as of December 31, 2024 of approximately $135 million, which is expected to be up from $69 million as of September 30, 2024 and up from $126 million as of December 31, 2023. This equates to a positive net cash position for 2024 as previously disclosed as part of our 2024 guidance.

Earnings

GENI

Genius Sports Reaffirms 2024 Guidance With $511M Revenue, $86M Adjusted EBITDA; Preliminary Cash Estimates Rise To $135M By Year-End

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher following December CPI data. CPI was in line with estimates, while core CPI rose by less than expected.

Benchmark analyst Subash Chandra reiterates Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Buy and maintains $93 price target.

Benchmark Reiterates Buy on Expand Energy, Maintains $93 Price Target

Former Palo Alto Networks CEO brings extensive technology and security experience to Blaize
Blaize Holdings, Inc. ("Blaize") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>), a provider of purpose-built, artificial intelligence ("AI")-enabled edge computing solutions, today announced the appointment of technology executive and investor Lane Bess as chairman of its board of directors.
Bess has over 35 years of experience as a successful operational executive, leading startups and helping to build some of the most iconic internet security companies. He is the former CEO of Palo Alto Networks, leading the company to its IPO. Later he played an instrumental role in leading Zscaler to its IPO. He also has held key positions in major companies such as Trend Micro Internet Security, NCR Corporation and AT&amp;T. His considerable work in the security technology sector has made him a trusted advisor for many enterprise technology CIOs and CISOs.
Lane's relationship with Blaize began more than three years ago when he became a key Blaize investor based on his conviction in semiconductor AI technology at the edge and his recognition of the significant potential of this emerging market.

Management

BZAI

Blaize Holdings Appoints Lane Bess As Chairman Of Its Board Of Directors

Gov. <a href="https://www.benzinga.com/real-estate/24/04/38046445/florida-governor-ron-desantis-raises-alarm-by-calling-citizens-insurance-not-solvent-as-an-explosive">Ron DeSantis</a> has a new pitch for Florida: bring NASA headquarters to the Sunshine State. Speaking at the Kennedy Space Center, he laid out a case that's as bold as practical. According to DeSantis, Washington D.C. isn't the right home for NASA anymore. Florida is.
"They have this massive building in D.C. and like nobody goes to it," DeSantis said in his signature direct style. His argument? NASA belongs where the action is – on Florida's Space Coast. "Why not just shutter it and move everyone down here?"
It's not just about geography. Florida is already a powerhouse in the aerospace industry. With 150,000 aerospace workers, three active spaceports and billions flowing into the state's economy, DeSantis says it's the logical next step.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum.<a href="https://www.benzinga.com/go/arrived-private-credit-yf"> </a></li>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks-y2">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
</ul>
"Hopefully, with the new administration coming in, they'll see a great opportunity to headquarter NASA on the Space Coast," he added, pointing out that Florida is home to the busiest spaceport in the world.
Rob Long, CEO of Space Florida, echoed that sentiment, saying Florida has the workforce, infrastructure and leadership to handle the nation's most <a href="https://www.benzinga.com/startups/24/12/42496960/elon-musk-tried-to-create-a-new-intergalactic-media-empire-called-thud-he-offered-2-million-to-onion-editors-and-poached-staff-away">important space operations</a>. "It makes logical sense to me to take the headquarters of the nation's space agency and put it in the state that is already leading across the space industry in general and in research and in talent," Long said.
But not everyone is sold on the idea. According to a CBS News article, Dr. Ken Kremer, a research scientist and editor of Space Up Close, warned that centralizing NASA in Florida could have long-term downsides. "It's bad policy for the public and it is bad politically," Kremer said. He explained that NASA's location in Washington ensures funding and political support from leaders nationwide. "If they concentrate everything in Florida, no one else will care."
See Also: Commercial real estate has historically outperformed the stock market, and<a href="https://equitymultiple.com/benzinga?invite=benzinga&amp;utm_campaign=product-promotion-earn&amp;utm_source=yahooFinance&amp;utm_medium=affiliate&amp;utm_content=stockmarket-yahoo"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
DeSantis didn't dive into specifics like a timeline or legislative plans, but his push to relocate NASA fits into Florida's broader efforts to dominate the space industry. Universities like the University of Florida, University of Central Florida and Embry-Riddle have already teamed up with the Kennedy Space Center to create the Florida University Space Research Consortium, which positions the state as a leader in space research grants.
Whether or not NASA makes the move, DeSantis's pitch underscores Florida's <a href="https://www.benzinga.com/real-estate/24/12/42716127/slapping-lipstick-on-a-pig-investors-are-snatching-up-hurricane-damaged-homes-in-florida-to-flip-but-concerns-rise-over-repair-quality">growing role in the space economy</a>. Space Florida estimates the state generates $1.1 billion annually from aerospace activities. For DeSantis, that's just the beginning.
So, while the nation debates the merits of moving NASA, the governor's message is simple: Florida's ready to launch.
Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today.<a href="https://smartasset.com/retirement/find-a-financial-planner?utm_source=benzinga&amp;utm_campaign=ben&amp;utm_content=y2_5MilNestEgg"> SmartAsset&#8217;s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost</a> to decide which one is right for you.
<h2 class="wp-block-heading">Interest Rates Are Falling, But These Yields Aren't Going Anywhere</h2>
Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities.
<a href="https://www.benzinga.com/go/arrived-private-credit-yf">Arrived Home's Private Credit Fund&#8217;s has historically paid an annualized dividend yield of 8.1%&#x2A;</a>, which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, <a href="https://www.benzinga.com/go/arrived-private-credit-yf">this one has a minimum investment of only $100.&nbsp;</a>
Looking for fractional real estate investment opportunities? The <a href="https://www.benzinga.com/alternative-investments/real-estate">Benzinga Real Estate Screener</a> features the latest offerings.

Real Estate

'Move Everyone Down Here' – Gov. Ron DeSantis Suggests Moving NASA From Washington D.C. To Florida Since 'Nobody Goes To It'

Macro Economic Events

Econ #s

Economics

CPI MoM For Dec. 0.4% Vs 0.4% Expected; 0.3% Prior

Macro Notification

US CPI (YoY) (Dec) +2.9% vs +2.9% Est.; +2.7% Prior

USA Core CPI (MoM) For Dec. 0.2% Vs 0.3% Est.; 0.3% Prior

USA Core CPI (YoY) For December 3.2% Vs 3.3% Est.; 3.3% Prior

Benchmark analyst Christopher Kuhn maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $150 to $155.

Benchmark Maintains Buy on XPO, Raises Price Target to $155

N2OFF, Inc.\ (NASDAQ:<a href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) (FSE:80W) ("N2OFF" and the "Company"), a clean tech company engaged in sustainable solutions for energy and agri-tech innovation, announced that its subsidiary Save Foods Ltd. ("Save Foods") was informed that opposition to its European patent EP2615932 filed by ECOLAB Inc. has been concluded in Save Foods' favor.
ECOLAB Inc. has the right to appeal this decision to the European Patent Register in by April 9, 2025.
The European patent covers a method of protecting edible matter using a specific performic acid composition, which is a significant part of Save Foods' proprietary technology and line of commercial solutions. Save Foods' commercial solutions are proven to extend shelf life of fresh produce while dramatically reducing, by at least 50%, the amount of hazardous pesticides.

Legal

NITO

N2OFF Was Informed That Opposition To Its European Patent EP2615932 Filed By ECOLAB Inc. Has Been Concluded In Save Foods' Favor; ECOLAB Inc. Has The Right To Appeal This Decision To The European Patent Register In By April 9, 2025.

Innovation Pharma

Comments

Innovation Pharma

Innovation Pharma (IPIX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga